Literature DB >> 9566710

Enhancement by antisense oligonucleotides to NF-kappaB of the differentiation of HL-60 promyelocytic leukemia cells induced by vitamin D3.

J A Sokoloski1, R Narayanan, A C Sartorelli.   

Abstract

We have demonstrated previously that a phosphorothioate antisense oligonucleotide to the p65 subunit of the inducible transcription factor NF-kappaB produced rapid changes in the expression of leukocyte integrin CD11b (Mo 1) and in the adhesion of dimethylsulfoxide (DMSO)-differentiated HL-60 cells stimulated by 12-O-tetradecanoylphorbol 13-acetate. We have also shown that a variety of agents which inhibit NF-kappaB, including vitamin E and related antioxidants, curcumin and several non-steroidal anti-inflammatory agents, significantly enhanced the differentiation of HL-60 leukemia cells when combined with low levels of 1,25-dihydroxyvitamin D3 (vitamin D3). To provide further evidence that interference with the activation of NF-kappaB affects the maturation of HL-60 leukemia cells by creating an environment conducive to terminal differentiation, we measured the effects of phosphorothioate antisense oligonucleotides to the various subunits of NF-kappaB on the differentiation of HL-60 cells produced by low levels of vitamin D3. When used alone these oligonucleotides had no significant effect on the differentiation of HL-60 cells. However, the antisense oligomer to the Rel A subunit of NF-kappaB markedly increased the extent of differentiation produced by low levels of vitamin D3. An enhancement of the differentiation of HL-60 cells induced by vitamin D3 was also obtained by several transcription factor decoys designed to mimic the consensus sequences of genes activated by Rel A. The findings provide additional support for the concept that inhibition of the activation of NF-kappaB may be involved in regulating the entry of promyelocytic leukemia cells into a differentiation pathway.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9566710     DOI: 10.1016/s0304-3835(97)00505-3

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  6 in total

1.  Cooperative antitumor effects of vitamin D3 derivatives and rosemary preparations in a mouse model of myeloid leukemia.

Authors:  Hagar Sharabani; Eugene Izumchenko; Qing Wang; Rita Kreinin; Michael Steiner; Zeev Barvish; Michael Kafka; Yoav Sharoni; Joseph Levy; Milan Uskokovic; George P Studzinski; Michael Danilenko
Journal:  Int J Cancer       Date:  2006-06-15       Impact factor: 7.396

2.  The Nrf2 transcription factor is a positive regulator of myeloid differentiation of acute myeloid leukemia cells.

Authors:  Irene Bobilev; Victoria Novik; Itai Levi; Ofer Shpilberg; Joseph Levy; Yoav Sharoni; George P Studzinski; Michael Danilenko
Journal:  Cancer Biol Ther       Date:  2011-02-01       Impact factor: 4.742

3.  Enhancement of 1 alpha,25-dihydroxyvitamin D(3)-induced differentiation of human leukaemia HL-60 cells into monocytes by parthenolide via inhibition of NF-kappa B activity.

Authors:  S N Kang; S H Kim; S W Chung; M H Lee; H J Kim; T S Kim
Journal:  Br J Pharmacol       Date:  2002-03       Impact factor: 8.739

4.  Resveratrol, a natural product derived from grapes, is a new inducer of differentiation in human myeloid leukemias.

Authors:  Hiroya Asou; Kozo Koshizuka; Taiichi Kyo; Noboru Takata; Nanao Kamada; H P Koeffier
Journal:  Int J Hematol       Date:  2002-06       Impact factor: 2.490

5.  Differential enhancement of leukaemia cell differentiation without elevation of intracellular calcium by plant-derived sesquiterpene lactone compounds.

Authors:  S H Kim; M Danilenko; T S Kim
Journal:  Br J Pharmacol       Date:  2008-08-25       Impact factor: 8.739

6.  5-Lipoxygenase inhibitors potentiate 1alpha,25-dihydroxyvitamin D3-induced monocytic differentiation by activating p38 MAPK pathway.

Authors:  Lenka Stixová; Jirina Procházková; Karel Soucek; Jirina Hofmanová; Alois Kozubík
Journal:  Mol Cell Biochem       Date:  2009-05-05       Impact factor: 3.396

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.